you are here: HomeNewsBiocon
biocon
Jump to
1508 Results Found
  • New launches to help Biocon Biologics reach $1 bn revenue target by FY22: Christiane Hamacher Jan 27, 2020 09:23 PM IST

    New launches to help Biocon Biologics reach $1 bn revenue target by FY22: Christiane Hamacher

    The biologics segment grew 50 percent year-on-year (YoY) in nine-month period to Rs 1594 crores, led primarily by contributions from Pegfilgrastim and Trastuzumab in US market.

  • Biocon tumbles 3% on 5 USFDA observations for Bengaluru unit Jan 27, 2020 10:27 AM IST

    Biocon tumbles 3% on 5 USFDA observations for Bengaluru unit

    Inspection of the Bengaluru facility took place between January 20 and January 24, 2020,

  • Biocon Consolidated December 2019 Net Sales at Rs 1,748.10 crore, up 13.45% Y-o-Y Jan 24, 2020 01:30 PM IST

    Biocon Consolidated December 2019 Net Sales at Rs 1,748.10 crore, up 13.45% Y-o-Y

  • Biocon Q3 profit down 7% at Rs 203 crore Jan 23, 2020 08:56 PM IST

    Biocon Q3 profit down 7% at Rs 203 crore

    Revenues rose YoY 14 percent to Rs 1784 crore in the third quarter.

  • Biocon Bengaluru unit pre-approval inspection by USFDA concludes with zero observations Jan 20, 2020 10:45 AM IST

    Biocon Bengaluru unit pre-approval inspection by USFDA concludes with zero observations

    The US Food and Drug Administration (USFDA) conducted a pre-approval inspection of the oral solid dosage manufacturing facility of Biocon Pharma, a subsidiary of Biocon, which was triggered by the submission of an abbreviated new drug application, the company said in a regulatory filing.

  • Biocon Biologics can achieve $1 bn revenue by 2022: Kiran Mazumdar Shaw Jan 07, 2020 01:30 PM IST

    Biocon Biologics can achieve $1 bn revenue by 2022: Kiran Mazumdar Shaw

    "We might raise little more private equity prior to IPO. This basically gives an idea of where we believe we can unlock the value in terms of Biocon Biologics in the next few years," she said.

  • Biocon appoints MB Chinappa as CFO of Biocon Biologics Jan 07, 2020 08:46 AM IST

    Biocon appoints MB Chinappa as CFO of Biocon Biologics

    Chinappa joins Biocon Biologics from another subsidiary company Syngene International, where he was President (Finance) and CFO since 2008

  • True North to acquire 2.44% stake in Biocon Biologics Jan 06, 2020 04:16 PM IST

    True North to acquire 2.44% stake in Biocon Biologics

    Biocon said it would use the proceeds of stake sale for expansion of R&D and manufacturing capabilities.

  • How Christiane Hamacher looks to steer Biocon Biologics towards $1 billion sales mark Jan 02, 2020 10:17 PM IST

    How Christiane Hamacher looks to steer Biocon Biologics towards $1 billion sales mark

    The company has set an ambitious target of clocking $1 billion in sales by FY22 through its biologics division, which is at near fourfold jump in terms of sales from FY19.

  • Market Headstart: Nifty is seen opening higher; HDFC Life, Avanti Feeds top buys Dec 13, 2019 08:11 AM IST

    Market Headstart: Nifty is seen opening higher; HDFC Life, Avanti Feeds top buys

    Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 30 points gain. Nifty futures were trading around 12,050 levels on the Singaporean Exchange

  • Biocon extends licensing pact for Itolizumab with Equillium for Australia, NZ Dec 12, 2019 07:02 PM IST

    Biocon extends licensing pact for Itolizumab with Equillium for Australia, NZ

    Equillium had secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017

  • This pharma stock is hot even after 39% rally Dec 03, 2019 02:45 PM IST

    This pharma stock is hot even after 39% rally

    Morgan Stanley has an overweight call on the stock, with a target price at Rs 350 per share.

  • Biocon share price rises 4% on launching cancer drug in US; Citi maintains buy Dec 03, 2019 09:42 AM IST

    Biocon share price rises 4% on launching cancer drug in US; Citi maintains buy

    Research house Citi has maintained buy rating on Biocon with a target at Rs 350 per share.

  • Market Headstart: Nifty seen opening flat; BEML, Kotak Mahindra Bank top buys Dec 03, 2019 08:13 AM IST

    Market Headstart: Nifty seen opening flat; BEML, Kotak Mahindra Bank top buys

    Trends on SGX Nifty indicate a negative opening for the broader index in India with a 17.5 points loss. Nifty futures were trading around 12,074-levels on the Singaporean Exchange

  • India Inc neither anti-national nor anti-government: Kiran Mazumdar Shaw Dec 02, 2019 07:50 PM IST

    India Inc neither anti-national nor anti-government: Kiran Mazumdar Shaw

    Shaw, who had earlier said the government treated India Inc as "pariahs" and doesn't want to hear any criticism of the economy, was responding to Finance Minister Nirmala Sitharman remarks that spreading one's own impression "can hurt national interest" in relation to the statement made by Bajaj on Saturday.

  • Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA Dec 02, 2019 06:42 PM IST

    Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA

    Ogivri was the first biosimilar of Herceptin to be approved by USFDA two years ago, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer.

  • USFDA approves Biocon drug Pegfilgrastim from new Bengaluru facility Nov 27, 2019 09:46 AM IST

    USFDA approves Biocon drug Pegfilgrastim from new Bengaluru facility

    "This is a significant milepost in our journey of serving 5 million patients by FY22 and crossing a revenue milestone of $1 billion," said Christiane Hamacher, CEO, Biocon Biologics.

  • Kiran Mazumdar Shaw: After meeting compliances, bizmen have no time to run cos Nov 22, 2019 06:32 PM IST

    Kiran Mazumdar Shaw: After meeting compliances, bizmen have no time to run cos

    The Biocon chief also flagged the deepening trust deficit between government and the industry saying there is an increasing tendency to criminalise every businessman.

  • Global brokerage view: 11% rally possible in Maruti stock; Titan downgraded to underperform Nov 06, 2019 10:44 AM IST

    Global brokerage view: 11% rally possible in Maruti stock; Titan downgraded to underperform

    The market has done well during recent times, caution may be required in the short-term, say experts.

  • Biocon gets EIR from USFDA for Bengaluru biologics unit Nov 05, 2019 10:39 AM IST

    Biocon gets EIR from USFDA for Bengaluru biologics unit

    The company had undergone good manufacturing norms compliance inspection of the unit from August 22-30, Biocon said in a regulatory filing.

  • Biocon number six in top 10 Global Biotech Employers ranking for 2019 Oct 28, 2019 05:40 PM IST

    Biocon number six in top 10 Global Biotech Employers ranking for 2019

    It continues to be the only company from Asia to feature on the prestigious US-based 'Science' magazine's annual 'Science Careers Top 20 Employers' list, since its debut in 2012.

  • Market Headstart: Nifty50 seen opening higher; HCL Tech, Hero MotoCorp eyed Oct 24, 2019 08:14 AM IST

    Market Headstart: Nifty50 seen opening higher; HCL Tech, Hero MotoCorp eyed

    Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 27.5 points gain or 0.24 percent. Nifty futures were trading around 11,666-level on the Singaporean Exchange.

  • Biocon Q2 net profit at Rs 216 cr Oct 23, 2019 08:40 PM IST

    Biocon Q2 net profit at Rs 216 cr

    Consolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration as against Rs 1,375.4 crore for the same period year ago.

  • Biocon gets 8 observations for 2 new biologics manufacturing units in Bengaluru Sep 20, 2019 08:26 PM IST

    Biocon gets 8 observations for 2 new biologics manufacturing units in Bengaluru

    The company is confident of addressing these observations effectively through a Corrective and Preventive Action (CAPA) plan, expeditiously, it added.

  • Biocon enters into pact with CMS to sell 3 generic products in China Sep 12, 2019 08:05 PM IST

    Biocon enters into pact with CMS to sell 3 generic products in China

    Biocon will be responsible for the development, manufacturing and supply of the products while CMS will be responsible for registration and commercialisation of the products in China.

Sections